UniPharma Co., Ltd. (6621.TWO)
Taipei Exchange · TWD · Healthcare · Drug Manufacturers - Specialty & Generic
NT$12.05 (+4.33%) as of
Key statistics
- Market cap
- 427.79M
- EPS (TTM)
- -1.13
- Dividend yield
- 0.00%
- 52-week range
- 10.50 – 16.00
- Beta
- -0.26
- Revenue (TTM)
- 83.87M
- Profit margin
- -47.80%
- Volume
- 99.67k
About UniPharma Co., Ltd.
UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and fomeject antidote injection, as well as drug development, research and development, clinical trials, marketing, and other business services. It serves medical centers, regional and area hospitals, and clinics. UniPharma Co., Ltd. was founded in 1998 and is based in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Taipei, Taiwan
- Employees
- 34
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.